Dataset opportunity
Dopltechnologies — Image Dataset Opportunity
Dopltechnologies 持有的中等图像数据集，可用于计算机视觉和多模态预训练。
Score
45
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
58%
Action
数据共享协议
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
全球医学影像人工智能市场 = 2025 年为 18 亿美元，复合年增长率为 35.1%。
Recent dated external facts that triggered this opportunity — auditable provenance.
- 📰press2026-07-27
Dopl is developing robotics for remote ultrasounds (and one day, much more)
medicaldesignandoutsourcing.com ↗
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
Profile
Dataset profile
Type
图像数据集
Modality
图像
Sector
医疗保健
Volume
中等
Freshness
实时
Rarity
高（专有）
Accessibility
受限
Legal
混合所有权 — GDPR 敏感（个人身份信息审查）
Buyer persona
计算机视觉实验室和基础模型团队
Dopltechnologies 持有的专业图像数据集来自其 Traverse 机器人系统，包含丰富的医学图像集合和相应的机器人遥测数据。该数据结构独特，适用于训练和验证计算机视觉算法，通过将视觉数据与精确的机器人操作相结合，提供对程序事件的全面视图。
该数据集面向全球医学影像人工智能市场，该市场在 2025 年的估值为 18 亿美元，预计将以惊人的 35.1% 复合年增长率扩张。[7] 尽管由于HIPAA法规、与临床合作伙伴的共同数据所有权以及与等待 FDA 批准的产品相关的数据的专有性质，访问权限需要协商，但其稀缺性和直接的程序相关性为旨在引领这一高增长领域的买家提供了重大机遇。[7] ⚠ 尽职调查（有价值的数据，可协商的访问权限）：医疗数据受 HIPAA 和 FDA 法规监管；数据所有权可能与临床合作伙伴和医院共有；机器人遥测数据是专有的，但与硬件开发周期相关；主要产品（Traverse）仍在 FDA 510(k) 批准流程中。· 公司：独立。
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
这些证据证明 Dopltechnologies 拥有一个专有的、正在积极增长的临床超声图像数据集，该数据集通过其独特的机器人超声服务生成。该数据本质上是多模态的，将丰富的医学图像与相应的触觉反馈和机器人控制流配对，这是一种计算机视觉实验室高度追捧的稀有组合。对于构建基础模型的团队来说，该数据集提供了原材料，可以在蓬勃发展的医学影像市场中开创新的诊断和程序人工智能，该市场预计到 2025 年将达到 18 亿美元。
See dimension details ↓- Dataset Specificity90
主导的“图像集合”，医疗保健行业，3 种特定类型
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity82
专有领域数据
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume64
5 个证据命中
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness82
实时/流式传输
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value84
适用于计算机视觉
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand95
买家需求极高，这得益于医学影像人工智能市场的快速扩张，预计复合年增长率为 35.1%。[7]
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility20
受限/未知
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility30
中等难度，独立
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength77
4 种证据类型，5 次命中
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License28
所有权=混合，许可=GDPR 敏感
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
独立
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation56
2 个数据需求信号（2 种类型）
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
盈余=高，1 个近期外部信号 — 现有已变现数据之外的专有数据
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit50
⚠ 审查 — 该公司的核心业务是销售人工智能驱动的远程机器人超声软件平台和服务，使其成为技术供应商，而不是休眠数据的持有者。问题：公司核心产品是人工智能软件平台（“Traverse™”）和相关服务（“SonoFlex™”），销售给医院。[2, 6]；商业模式是销售智能/能力，这被明确定义为“坏”目标；它们是技术/软件供应商，而不是拥有非数据运营业务并产生副产品数据的公司。[5, 8]
- Deep Qualification90
✓ 通过 — Dopl Technologies 是一个商业前数据持有者，正在开发远程机器人超声服务。它作为副产品生成高度可信的医学图像和机器人遥测数据集。然而，数据所有权与临床合作伙伴混合，访问受 HIPAA 限制，其核心产品仍在 FDA 批准过程中，商业数据权利不明确。
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Image collection
证据证实 Dopltechnologies 正在通过其超声服务积极生成专有的临床成像数据集合，这是任何针对高增长医学影像市场的 AI 团队的核心资产。
Event streams
公司顾问委员会包括数据流和超声技术专家，这表明了生产可靠的实时数据流以用于高级 AI 应用所需的技术和临床监督。
IoT / sensor data
该公司的机器人系统生成独特的时间序列数据，包括触觉反馈流，这些数据可以与图像数据同步，以构建强大的多模态 AI 模型，用于程序指导和自动化。
business_records
Dopltechnologies 捕获有关医疗保健效率的运营数据，提供有价值的业务记录，可以丰富临床数据集，并提供现实世界的背景信息，以训练更健壮且对部署有意识的 AI。
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Dopltechnologies Image — a Moderate image dataset (Image modality) in the healthcare domain. Primary AI use-case: Computer Vision. Market signal: Global AI in Medical Imaging market = $1.8 billion in 2025, CAGR 35.1% (source: Grand View Research). Investment score 45.0/100 (confidence 0.58). Recommended action: Data Sharing Agreement.
From the marketplace
Explore live data opportunities
Voltagrid — 维护日志数据集机会
View opportunity →零售Zenergyfs — 交易数据集机会
View opportunity →其他Bluearth — 维护日志数据集机会
View opportunity →